Multiple Myeloma

Timothy M. Schmidt, MD, discusses the utilization of bispecific antibodies in myeloma.

Natalie S. Callander, MD, discusses selecting a frontline treatment strategy for patients with multiple myeloma.

Kathleen A. Dorritie, MD, details the utility of minimal residual disease in multiple trials in the multiple myeloma space.

Andrew Spencer, MD, MBBS, FRACP, FRCPA discusses the significance of the PANORAMA 3 study in multiple myeloma.

Yi Lin, MD, PhD, discusses the importance of developing non-BCMA–targeting agents in multiple myeloma.

Shaji K. Kumar, MD, discusses the emergence of minimal residual disease negativity as a surrogate end point in relapsed/refractory multiple myeloma.

Sagar Lonial, MD, discussed key facets of belantamab mafodotin and potential next steps.

Parameswaran Hari, MD, MRCP, discusses treatment strategies for patients with relapsed/refractory multiple myeloma.

Rafael Fonseca, MD, weighs the risks and benefits of quadruplet regimens in patient with multiple myeloma.

In our exclusive interview, Dr. Kansagra, Dr. D’Souza, and Dr. Dholaria provided an in-depth look into the current state of cellular therapy in hematologic malignancies, the benefits and drawbacks of approved and investigational products, and new constructs for CAR T in multiple myeloma and lymphoma.

Rafael Fonseca, MD, discusses key data in multiple myeloma.

Shaji K. Kumar, MD, discusses the importance of understanding the safety profiles of combination therapies in multiple myeloma.

Edward A. Stadtmauer, MD, highlights the emergence of several BCMA-directed therapies, such as monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies, and how outcomes for patients with multiple myeloma have improved significantly.

Sikander Ailawadhi, MD, discusses the emergence of T-cell engagers in multiple myeloma.